Vascular Disease

Categories: Blood diseases, Cardiovascular diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Vascular Disease

MalaCards integrated aliases for Vascular Disease:

Name: Vascular Disease 12 15 17
Vascular Diseases 54 42 43 15 71
Spinal Cord Ischemia 43 17 71
Spinal Cord Vascular Diseases 43 71
Aneurysm 43 71
Vascular Tissue Disease 12
Vascular Anomaly 54


External Ids:

Disease Ontology 12 DOID:178
ICD9CM 34 442.9
ICD10 32 I72.9
UMLS 71 C0002940 C0042373 C0752127 more

Summaries for Vascular Disease

MedlinePlus : 42 What are vascular diseases? Your vascular system is your body's network of blood vessels. It includes your Arteries, which carry oxygen-rich blood from your heart to your tissues and organs Veins, which carry the blood and waste products back to your heart Capillaries, which are tiny blood vessels that connect your small arteries to your small veins. The walls of the capillaries are thin and leaky, to allow for an exchange of materials between your tissues and blood. Vascular diseases are conditions which affect your vascular system. They are common and can be serious. Some types include Aneurysm - a bulge or "ballooning" in the wall of an artery Atherosclerosis - a disease in which plaque builds up inside your arteries. Plaque is made up of fat, cholesterol, calcium, and other substances found in the blood. Blood clots, including deep vein thrombosis and pulmonary embolism Coronary artery disease and carotid artery disease, diseases that involve the narrowing or blockage of an artery. The cause is usually a buildup of plaque. Raynaud's disease - a disorder that causes the blood vessels to narrow when you are cold or feeling stressed Stroke - a serious condition that happens when blood flow to your brain stops. Varicose veins - swollen, twisted veins that you can see just under the skin Vasculitis - inflammation of the blood vessels What causes vascular diseases? The causes of vascular diseases depend on the specific disease. These causes include Genetics Heart diseases such as high cholesterol and high blood pressure Infection Injury Medicines, including hormones Sometimes the cause is unknown. Who is at risk for vascular diseases? The risk factors for vascular diseases can vary, depending on the specific disease. But some of the more common risk factors include Age - your risk of some diseases goes up as you get older Conditions that can affect the heart and blood vessels, such as diabetes or high cholesterol Family history of vascular or heart diseases Infection or injury that damages your veins Lack of exercise Obesity Pregnancy Sitting or standing still for long periods of time Smoking What are the symptoms of vascular diseases? The symptoms for each disease are different. How are vascular diseases diagnosed? To make a diagnosis, your health care provider will do a physical exam and ask about your symptoms and medical history. You may have imaging tests and/or blood tests. How are vascular diseases treated? Which treatment you get depends on which vascular disease you have and how severe it is. Types of treatments for vascular diseases include Lifestyle changes, such as eating a heart-healthy diet and getting more exercise Medicines, such as blood pressure medicines, blood thinners, cholesterol medicines, and clot-dissolving drugs. In some cases, providers use a catheter to send medicine directly to a blood vessel. Non-surgical procedures, such as angioplasty, stenting, and vein ablation Surgery Can vascular diseases be prevented? There are steps you can take to help prevent vascular diseases: Make healthy lifestyle changes, such as eating a heart-healthy diet and getting more exercise Don't smoke. If you are already a smoker, talk to your health care provider for help in finding the best way for you to quit. Keep your blood pressure and cholesterol in check If you have diabetes, control your blood sugar Try not to sit or stand for up long periods of time. If you do need to sit all day, get up and move around every hour or so. If you traveling on a long trip, you can also wear compression stockings and regularly stretch your legs.

MalaCards based summary : Vascular Disease, also known as vascular diseases, is related to peripheral vascular disease and intracranial berry aneurysm, and has symptoms including edema, chest pain and angina pectoris. An important gene associated with Vascular Disease is MIR145 (MicroRNA 145), and among its related pathways/superpathways are Folate Metabolism and Fluid shear stress and atherosclerosis. The drugs Ticlopidine and Spironolactone have been mentioned in the context of this disorder. Affiliated tissues include endothelial, heart and smooth muscle, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A cardiovascular system disease that primarily affects the blood vessels which includes the arteries, veins and capillaries that carry blood to and from the heart.

Wikipedia : 74 Vascular disease is a class of diseases of the blood vessels - the arteries and veins of the circulatory... more...

Related Diseases for Vascular Disease

Diseases in the Vascular Disease family:

Rare Vascular Disease

Diseases related to Vascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2492)
# Related Disease Score Top Affiliating Genes
1 peripheral vascular disease 35.6 VWF VEGFA VCAM1 SERPINE1 SELP NOS3
2 intracranial berry aneurysm 35.5 VWF VCAM1 NOS3 EDN1 CRP APOE
3 hepatic vascular disease 35.1 VWF VEGFA SERPINE1 NOS3 MIR214 EDN1
4 retinal vascular disease 35.0 VEGFA VCAM1 NOS3 MTHFR MIR21 INS
5 buerger disease 34.2 SERPINE1 NOS3 MTHFR
6 polycystic kidney disease 33.9 VEGFA NOS3 EDN1 ACE
7 arteriosclerosis 33.8 VCAM1 SERPINE1 SELP PON1 NOS3 MIR21
8 autosomal dominant polycystic kidney disease 33.7 VEGFA VCAM1 NOS3 INS EDN1 ACE
9 cerebrovascular disease 33.6 VWF VCAM1 SERPINE1 SELP PON1 MTHFR
10 portal vein thrombosis 33.6 SERPINE1 SELP MTHFR CRP
11 vein disease 33.5 VWF VEGFA SERPINE1 SELP MTHFR INS
12 thrombosis 33.5 VWF VCAM1 SERPINE1 SELP NOS3 MTHFR
13 vasculitis 33.4 VWF VCAM1 SELP CRP
14 ischemia 33.3 VEGFA SELP PON1 NOS3 MIR21 EDN1
15 carpal tunnel syndrome 33.2 VEGFA INS ACE
16 chronic thromboembolic pulmonary hypertension 33.1 EDN1 CRP
17 intermittent claudication 33.1 VWF VEGFA SERPINE1 SELP CRP ACE
18 arteriosclerosis obliterans 33.0 VCAM1 SELP MIR21
19 hereditary hemorrhagic telangiectasia 33.0 VWF VEGFA NOS3 ACVRL1
20 angiodysplasia 32.9 VWF VEGFA ACVRL1
21 cholesterol embolism 32.7 CRP ACE
22 atherosclerosis susceptibility 32.6 VWF VEGFA VCAM1 SERPINE1 SELP PON1
23 peripheral artery disease 32.4 VWF VEGFA VCAM1 SELP NOS3 EDN1
24 homocysteinemia 32.4 VWF VCAM1 SERPINE1 PON1 NOS3 MTHFR
25 raynaud disease 32.3 EDN1 CRP ACE
26 coronary heart disease 1 32.3 VWF VCAM1 SERPINE1 SELP PON1 NOS3
27 aortic valve disease 1 32.2 VWF NOS3 MIR21 EDN1 ACE
28 chronic kidney disease 32.2 VEGFA VCAM1 SERPINE1 PON1 NOS3 MTHFR
29 carotid stenosis 32.2 VEGFA VCAM1 SELP NOS3 MTHFR CRP
30 kidney disease 32.2 VCAM1 SERPINE1 PON1 NOS3 MTHFR INS
31 arteries, anomalies of 32.2 VWF VEGFA VCAM1 SERPINE1 NOS3 MIR214
32 hypercholesterolemia, familial, 1 32.2 NOS3 INS CRP APOE ACE
33 pre-eclampsia 32.1 VWF VEGFA VCAM1 SERPINE1 SELP PON1
34 diabetes mellitus 32.1 VWF VEGFA VCAM1 SERPINE1 SELP PON1
35 end stage renal disease 32.1 VEGFA PON1 NOS3 INS CRP ACE
36 vascular dementia 32.1 VWF VEGFA PON1 MTHFR CRP APOE
37 stroke, ischemic 32.1 VWF VEGFA SERPINE1 SELP PON1 NOS3
38 pulmonary hypertension 32.1 VWF VEGFA SERPINE1 SELP NOS3 MIR21
39 pericardial effusion 32.0 VEGFA CRP ACE
40 carotid artery disease 32.0 VWF SELP PON1 CRP APOE ACE
41 lipid metabolism disorder 32.0 SERPINE1 PON1 MIR21 INS CRP APOE
42 microvascular complications of diabetes 5 32.0 VEGFA VCAM1 SERPINE1 PON1 NOS3 MIR21
43 retinal vein occlusion 32.0 VEGFA SERPINE1 MTHFR EDN1 ACE
44 aortic aneurysm, familial abdominal, 1 32.0 CRP APOE ACE
45 lung disease 32.0 VEGFA INS EDN1 CRP ACE
46 impotence 31.9 VEGFA NOS3 INS EDN1 ACE
47 congestive heart failure 31.9 VEGFA NOS3 INS EDN1 CRP ACE
48 limb ischemia 31.9 VWF VEGFA SERPINE1 NOS3 MIR21 EDN1
49 pulmonary embolism 31.9 VWF SERPINE1 MTHFR CRP ACE
50 systemic scleroderma 31.8 SELP MIR21 INS EDN1 CRP ACE

Graphical network of the top 20 diseases related to Vascular Disease:

Diseases related to Vascular Disease

Symptoms & Phenotypes for Vascular Disease

UMLS symptoms related to Vascular Disease:

edema, chest pain, angina pectoris, flushing, leg cramps, warm skin, vein pain

MGI Mouse Phenotypes related to Vascular Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.07 ACE ACVRL1 APOE CRP EDN1 INS
2 homeostasis/metabolism MP:0005376 10 ACE ACVRL1 APOE CRP EDN1 INS
3 liver/biliary system MP:0005370 9.61 ACE ACVRL1 APOE INS MTHFR NOS3
4 renal/urinary system MP:0005367 9.28 ACE ACVRL1 APOE EDN1 INS NOS3

Drugs & Therapeutics for Vascular Disease

Drugs for Vascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 807)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Ticlopidine Approved Phase 4 55142-85-3 5472
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
Chlorthalidone Approved Phase 4 77-36-1 2732
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
Famotidine Approved Phase 4 76824-35-6 3325
Dinoprostone Approved Phase 4 363-24-6 5280360
Testosterone enanthate Approved Phase 4 315-37-7 9416
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
Methyltestosterone Approved Phase 4 58-18-4 6010
Atorvastatin Approved Phase 4 134523-00-5 60823
Nicotine Approved Phase 4 54-11-5 942 89594
Piperacillin Approved Phase 4 66258-76-2 43672
Remifentanil Approved Phase 4 132875-61-7 60815
Gliclazide Approved Phase 4 21187-98-4 3475
Ambrisentan Approved, Investigational Phase 4 177036-94-1 6918493
Nebivolol Approved, Investigational Phase 4 99200-09-6, 118457-14-0, 152520-56-4 71301
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
Iodine Approved, Investigational Phase 4 7553-56-2 807
Atenolol Approved Phase 4 29122-68-7 2249
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
Amlodipine Approved Phase 4 88150-42-9 2162
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
Travoprost Approved Phase 4 157283-68-6 5282226
Vorapaxar Approved Phase 4 618385-01-6
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
Ofloxacin Approved Phase 4 82419-36-1 4583
Dobutamine Approved Phase 4 34368-04-2 36811
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
Donepezil Approved Phase 4 120014-06-4 3152
Calcium acetate Approved, Investigational Phase 4 62-54-4
Sevelamer Approved Phase 4 52757-95-6
Capsaicin Approved Phase 4 404-86-4 1548943
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
Enoxaparin Approved Phase 4 9005-49-6 772
Glyburide Approved Phase 4 10238-21-8 3488
Phenprocoumon Approved, Investigational Phase 4 435-97-2 54680692 9908
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
Allopurinol Approved Phase 4 315-30-0 2094
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5362032
Enalaprilat Approved Phase 4 76420-72-9 6917719
Metronidazole Approved Phase 4 443-48-1 4173
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
Ibuprofen Approved Phase 4 15687-27-1 3672

Interventional clinical trials:

(show top 50) (show all 3745)
# Name Status NCT ID Phase Drugs
1 Randomized Trial of Paclitaxel Eluting Balloon or Conventional Balloon for Treatment of In-Stent Restenosis of the Superficial Femoral Artery in Patients With Symptomatic Peripheral Artery Disease (ISAR-PEBIS) Unknown status NCT01083394 Phase 4
2 Randomized Trial of Stenting After Dilation With or Without Paclitaxel Eluting Balloon or Atherectomy in Patients With Symptomatic Peripheral Artery Disease Unknown status NCT00986752 Phase 4
3 Evaluation of Closed Incision Negative Pressure Device (Prevena) to Prevent Vascular Wound Complications Unknown status NCT02581904 Phase 4
4 Phase 4 Study of Medical Therapy Versus Medical Therapy Plus Renal Artery Stenting in Preventing the Progression of Renal Failure in Atherosclerotic Renovascular Disease Unknown status NCT01023373 Phase 4 Medical treatment
5 The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery for the Treatment The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery of Femoropopliteal TASC C&D Lesions Unknown status NCT01952457 Phase 4
6 The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV) Unknown status NCT03159884 Phase 4 Conbercept
7 Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV) Unknown status NCT02860858 Phase 4
8 Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being Unknown status NCT02796378 Phase 4 Training+Simvastatin+Q10-placebo;Training+Simvastatin-placebo+Q10-placebo;Training+Simvastatin+Q10
9 Eplerenone in the Management of Abdominal Aortic Aneurysms: A Proof-Of-Concept Randomised Controlled Trial Unknown status NCT02345590 Phase 4 Eplerenone
10 The Effect of Immunonutrition on Outcome and Postoperative Recovery in Patients Undergoing Elective Surgical Repair of a Thoraco (Abdominal) Aneurysm Aorta Unknown status NCT00339053 Phase 4 Immunonutrition ( Impact)
11 Comparative Study of Covered Stent With Coil Embolization in the Treatment of Cranial Internal Carotid Artery Aneurysm: A Nonrandomized Prospective Trial Unknown status NCT01029938 Phase 4
12 Platelets Induced Vasodilation, in Vitro and in Vivo Study in Patients With Arteriopathy and Healthy Subjects. Unknown status NCT00152646 Phase 4 placebo, aspirine, clopidogrel
13 SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial Unknown status NCT02959606 Phase 4 Sarpogrelate SR 300mg;Clopidogrel
14 Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part I) Unknown status NCT01171703 Phase 4
15 Delayed Vasospasm After Aneurysm With the Standardization Treatment of Traditional Chinese Medicine Unknown status NCT01840761 Phase 4 herbal drug;placebo
16 Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis (PESETA) Unknown status NCT02033135 Phase 4
17 Exploratory Study to Assess the Efficacy of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
18 DCLI-II:Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part II) Unknown status NCT01173094 Phase 4
19 Study of the OmniWave Endovascular System in Subjects With Lower and Upper Extremity Deep Vein Thrombosis - SONIC I Study Unknown status NCT00640731 Phase 4
20 Multicenter Clinical Study Assessing the Performance and the Safety of the Second Generation Antimicrobial Graft in the Abdominal Position Unknown status NCT00824109 Phase 4
21 Prophylactic Mesh Implantation After Abdominal Aortic Aneurysm Repair. A Prospective, Randomised, Controlled Study Unknown status NCT01353443 Phase 4
22 Early Warning and Optimization Strategy in Carotid Endarterectomy Unknown status NCT01210937 Phase 4
23 The Difference of Circulating Endothelial-derived and Platelet-derived Microparticles in Patients With Psoriasis Successfully Treated With Stelara(Ustekinumab) Unknown status NCT02693470 Phase 4 Ustekinumab
24 Randomized Controlled Trial to Evaluate Implanted Event Recorders for the First Diagnosis of Atrial Fibrillation in High-risk Patients Unknown status NCT01461434 Phase 4
25 Open-label, Non-randomized, Unmasked, Study of IAI in Patients Which Choroidal Neovascularization Secondary to Polypoidal Choroidal Vasculopathy (PCV) Unknown status NCT02092532 Phase 4 Rescue Intravitreal Aflibercept Injection
26 Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal Vasculopathy Unknown status NCT03244657 Phase 4 conbercept ophthalmic injection (0.5mg);conbercept ophthalmic injection (0.5mg)
27 Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function Unknown status NCT02584075 Phase 4 Byetta (Exenatide);Glucophage ( Metformin Hydrochloride)
28 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Unknown status NCT02478346 Phase 4 Fluorescein Sodium
29 Device Closure Versus Medical Therapy for Secondary Prevention in Cryptogenic Stroke Patients With High-Risk Patent Foramen Ovale : DEFENSE-PFO Unknown status NCT01550588 Phase 4 Standard medical treatment
30 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
31 Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial) Unknown status NCT02660866 Phase 4 Placebo + background APT + SMT;Vorapaxar 2.08 mg/d + background APT + SMT.
32 A Randomized Controlled Trial Comparing Usual Care With a Multifactorial Intensified Intervention on Cardiovascular Risk Factors in Subjects With Arterial Peripheral Disease With and Without Diabetes. The Taulí Intervention Program (TIP). Unknown status NCT00144937 Phase 4 Stepwise therapy for dyslipidemia, hypertension and diabetes
33 The Study to Compare the Treatment of Stent and Prothesis Bypass in SFA Occlusions Unknown status NCT01147419 Phase 4
34 Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin Unknown status NCT03195153 Phase 4 Atorvastatin 80mg;ALLOPURINOL 300 MG;Atorvastatin 80mg AND allopurinol 300 mg
35 Regulation of Bone Mineralization in Renal Osteodystrophy Unknown status NCT01799317 Phase 4 Vitamin D2
36 A Prospective Randomized Multicenter Study of the Efficacy and Safety of Systematic Post -Dilatation With Noncompliant Balloon After Successful Drug-eluting Stent Implantation. IVUS Analysis. Unknown status NCT01103765 Phase 4
37 The Effects of Pravastatin and Rosuvastatin on the Tissue Characteristics and Morphology of Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
38 Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis Unknown status NCT01823185 Phase 4 clopidogrel;Ticagrelor or prasugrel
39 A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
40 A Randomised Controlled Trial of the Effectiveness of Acetazolamide in Reducing Cerebrospinal Fluid Pressure for Patients Undergoing Thoracic-abdominal Aortic Repair Unknown status NCT01889498 Phase 4 Acetazolamide
41 A Randomised Controlled Trial of the Effectiveness of Ultrasound Guidance in Cannulation of Dialysis Arteriovenous Fistulas and Grafts in a University Hospital Dialysis Unit Unknown status NCT01163981 Phase 4
42 Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions Unknown status NCT00698607 Phase 4 6-month clopidogrel therapy;12-month clopidogrel therapy
43 Tailored Strategy for Residual Platelet Activity In Advanced Peripheral Artery Disease: New Optimal Management. Unknown status NCT01627431 Phase 4 Acetylsalicylic acid;Clopidogrel
44 Efficacy of Self-Expanding Nitinol S.M.A.R.T CONTROLTM Stent Versus Life Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease : Prospective, Multicenter, Randomized, Controlled Trial (SENS-FP-2 Trial) Unknown status NCT01653600 Phase 4
45 Esomeprazole or Famotidine in the Management of Aspirin Related Non-ulcer Dyspepsia - a Double Blind Randomized Control Study Unknown status NCT00978159 Phase 4 esomeprazole;Famotidine
46 A Clinical Study on Anti-Hypertensive Agent (ACEi) and Heart Function Improvement Unknown status NCT01069042 Phase 4 Enalapril
47 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
48 Randomised Clinical Trial to Evaluate the Obtention of Blood Samples Through an Arterial Catheter to Monitor Glycose Levels Unknown status NCT01176279 Phase 4
49 Glibenclamide in Aneurysmatic Subarachnoid Hemorrhage: A Prospective and Randomized Study Unknown status NCT03569540 Phase 4 Glibenclamide
50 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA

Search NIH Clinical Center for Vascular Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cochrane evidence based reviews: aneurysm

Genetic Tests for Vascular Disease

Anatomical Context for Vascular Disease

MalaCards organs/tissues related to Vascular Disease:

Endothelial, Heart, Smooth Muscle, Kidney, Brain, Lung, Testes

Publications for Vascular Disease

Articles related to Vascular Disease:

(show top 50) (show all 40422)
# Title Authors PMID Year
MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. 46 61
19542014 2009
MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. 46 61
17478730 2007
Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells. 54 61
20232317 2010
EGCG protects against oxidized LDL-induced endothelial dysfunction by inhibiting LOX-1-mediated signaling. 61 54
20203069 2010
Notch and transforming growth factor-beta (TGFbeta) signaling pathways cooperatively regulate vascular smooth muscle cell differentiation. 61 54
20368328 2010
Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. 61 54
20421882 2010
Migraine and coronary artery disease: an open study on the genetic polymorphism of the 5, 10 methylenetetrahydrofolate (MTHFR) and angiotensin I-converting enzyme (ACE) genes. 54 61
20518725 2010
Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment. 54 61
20079523 2010
Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model. 54 61
20466987 2010
Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. 54 61
20164116 2010
Microvascular complications are associated with low levels of maternal sE-selectin and sVCAM-1 in pregnancy complicated with pregestational diabetes mellitus. 54 61
20129688 2010
Vascular oxidative stress: the common link in hypertensive and diabetic vascular disease. 61 54
20422735 2010
Association of apolipoprotein B with incident type 2 diabetes in an aboriginal Canadian population. 54 61
20110448 2010
Weighting the potential of using tenascin C in diagnosis and therapy of atherosclerosis. 61 54
20513936 2010
Genetic variants promoting smooth muscle cell proliferation can result in diffuse and diverse vascular diseases: evidence for a hyperplastic vasculomyopathy. 61 54
20130469 2010
High glucose and elevated fatty acids suppress signaling by the endothelium protective ligand angiopoietin-1. 54 61
20079751 2010
APOH is increased in the plasma and liver of type 2 diabetic patients with metabolic syndrome. 61 54
19878946 2010
Upregulation of heme oxygenase-1 inhibits the maturation and mineralization of osteoblasts. 61 54
20020468 2010
JNK-ATF-2 inhibits thrombomodulin (TM) expression by recruiting histone deacetylase4 (HDAC4) and forming a transcriptional repression complex in the TM promoter. 54 61
20116378 2010
Visfatin, glucose metabolism and vascular disease: a review of evidence. 54 61
20346149 2010
An overview of the Guangzhou biobank cohort study-cardiovascular disease subcohort (GBCS-CVD): a platform for multidisciplinary collaboration. 61 54
19587700 2010
The association between the -374T/A polymorphism of the receptor for advanced glycation endproducts gene and blood pressure and arterial stiffness is modified by glucose metabolism status: the Hoorn and CoDAM studies. 61 54
20051912 2010
Endothelial nitric oxide synthase and nicotinamide adenosine dinucleotide phosphate oxidase p22phox gene (C242T) polymorphisms and systemic lupus erythematosus in a Chinese Population. 61 54
19965945 2010
Haptoglobin phenotype correlates with the extent of cerebral deep white matter lesions in hypertensive patients. 61 54
20158468 2010
Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease. 54 61
20204740 2010
Plasma homocysteine, apolipoprotein E status and vascular disease in elderly patients with mental illness. 54 61
19943806 2010
C-reactive protein gene variant and the human left ventricular growth response to exercise: data from The LARGE Heart Study. 61 54
19834334 2010
Paraoxonase 1 status as a risk factor for disease or exposure. 54 61
20221868 2010
Genetic predisposition to advanced glycation end products toxicity is related to prognosis of chronic hemodialysis patients. 61 54
20185929 2010
The connection between C-reactive protein (CRP) and diabetic vasculopathy. Focus on preclinical findings. 61 54
20034371 2010
The protective role of adiponectin in pulmonary vascular disease. 54 61
19880503 2010
Telmisartan in high-risk cardiovascular patients. 61 54
20102972 2010
The impact of macrophage insulin resistance on advanced atherosclerotic plaque progression. 61 54
20056946 2010
Homocysteine promotes vascular smooth muscle cell migration by induction of the adipokine resistin. 54 61
19828833 2009
Non-arteritic anterior ischemic optic neuropathy (NA-AION) after intravitreal injection of bevacizumab (Avastin) for treatment of angoid streaks in pseudoxanthoma elasticum. 61 54
19916212 2009
Adenosine blocks IFN-gamma-induced phosphorylation of STAT1 on serine 727 to reduce macrophage activation. 61 54
19846878 2009
Association of serum osteoprotegerin with ankle-brachial index and urine albumin: creatinine ratio in African-Americans and non-Hispanic whites. 54 61
19423112 2009
Insulin glargine reduces carotid intimal hyperplasia after balloon catheter injury in Zucker fatty rats possibly by reduction in oxidative stress. 54 61
19360379 2009
Coordinated regulation of angiopoietin-1 and vascular endothelial growth factor by arsenite in human brain microvascular pericytes: implications of arsenite-induced vascular dysfunction. 54 61
19622383 2009
Distribution of endothelial nitric oxide synthase gene polymorphisms in Turkish population. 54 61
19730129 2009
Investigation of SERPINE1 genetic polymorphism in Macedonian patients with occlusive artery disease and deep vein thrombosis. 61 54
20017074 2009
Endoglin haploinsufficiency reduces radiation-induced fibrosis and telangiectasia formation in mouse kidneys. 54 61
19576647 2009
Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: a link between coagulation and inflammation. 54 61
19652200 2009
Tissue factor gene polymorphisms and haplotypes and the risk of ischemic vascular events: four studies and a meta-analysis. 54 61
19583819 2009
Safety and tolerability of bosentan in the management of pulmonary arterial hypertension. 54 61
19920927 2009
Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. 54 61
19778663 2009
A-G-4G haplotype of PAI-1 gene polymorphisms -844 G/A, HindIII G/C, and -675 4G/5G is associated with increased risk of ischemic stroke caused by small vessel disease. 61 54
19154538 2009
Aspirin reduces the prothrombotic activity of C-reactive protein. 54 61
19522741 2009
Haemostatic markers are associated with measures of vascular disease in adults with hypertension. 54 61
19190656 2009
Posttranslational modification of constitutive nitric oxide synthase in the penis. 54 61
19342700 2009